发明授权
US08288407B2 Substituted naphthyridine compounds as inhibitors of Akt activity
有权
取代的萘啶化合物作为Akt活性的抑制剂
- 专利标题： Substituted naphthyridine compounds as inhibitors of Akt activity
- 专利标题（中）： 取代的萘啶化合物作为Akt活性的抑制剂
-
申请号： US13046322申请日： 2011-03-11
-
公开(公告)号： US08288407B2公开(公告)日： 2012-10-16
- 发明人: Michael J. Kelly, III , Mark E. Layton , Philip E. Sanderson
- 申请人： Michael J. Kelly, III , Mark E. Layton , Philip E. Sanderson
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Yong Zhao; David A. Muthard; Matthew A. Leff
- 主分类号： C07D471/14
- IPC分类号： C07D471/14 ; A61K31/437 ; A61P35/00
摘要：
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. Compounds disclosed herein have the following chemical structure:
公开/授权文献
- US20110160183A1 INHIBITORS OF AKT ACTIVITY 公开/授权日：2011-06-30
信息查询
